Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2019

View Archived Issues

APPBP2 as a novel therapeutic target in NSCLC

Selective targeting of PARP-2 inhibits AR-positive prostate cancer growth

Myocardial ischemia/reperfusion injury is reduced by prostacyclin analogue-loaded nanoparticles

AAV-eCD4-Ig protects rhesus macaques from SIVmac239 challenges

Commensal Neisseria fight pathogenic relatives in "tribal warfare"

Positive interim data presented for AAV gene therapy in children with CLN6 Batten disease

AZD-0530 shows no statistically significant effect on cerebral metabolic decline in AD

First-in-human data presented for the zwitterionic near-infrared fluorophore ZW800-1

JMJD6 as a novel therapeutic target in neuroblastoma

Rewind Therapeutics to discover drugs for myelin-related neurological diseases

Phase I study of PN-943 demonstrates sustained dose-related target engagement activity

Promedior presents phase II data on PRM-151 in patients with IPF

Zeno Royalties & Milestones patents Bcl-2 inhibitors

Lifesci Pharmaceuticals divulges KLKB1 inhibitors

Momenta Pharmaceuticals launches phase II/III study of nipocalimab in wAIHA

Integral BioSciences discloses new TGFR-1 and MAPK14 inhibitors

Aurigene Discovery Technologies describes new anticancer agents

New glucose-lowering compounds presented by Daiichi Sankyo

First patient dosed in phase IIa study of ABX-464 for the treatment of RA

Prokaryotics receives support for its immune potentiation program

Novartis initiates first-in-human trial of CD19-specific CAR-T cells

Recruitment ongoing in phase I study of BI-754132

T20K demonstrates favorable safety and tolerability in first-in-human study

IDMC recommends stopping PHOCUS study of Pexa-Vec